These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 26684803)

  • 1. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
    Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
    Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor cells found in patients with localized and advanced pancreatic cancer.
    Kulemann B; Pitman MB; Liss AS; Valsangkar N; Fernández-Del Castillo C; Lillemoe KD; Hoeppner J; Mino-Kenudson M; Warshaw AL; Thayer SP
    Pancreas; 2015 May; 44(4):547-50. PubMed ID: 25822154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
    Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
    BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Circulating tumor cells in pancreatic cancer : Results of morphological and molecular analyses and comparisons with the primary tumor].
    Timme-Bronsert S; Bronsert P; Werner M; Kulemann B; Höppner J
    Pathologe; 2018 Dec; 39(Suppl 2):311-314. PubMed ID: 30483865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
    Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
    World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer.
    Ankeny JS; Court CM; Hou S; Li Q; Song M; Wu D; Chen JF; Lee T; Lin M; Sho S; Rochefort MM; Girgis MD; Yao J; Wainberg ZA; Muthusamy VR; Watson RR; Donahue TR; Hines OJ; Reber HA; Graeber TG; Tseng HR; Tomlinson JS
    Br J Cancer; 2016 Jun; 114(12):1367-75. PubMed ID: 27300108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Portal Venous Blood Circulation Supports Immunosuppressive Environment and Pancreatic Cancer Circulating Tumor Cell Activation.
    Arnoletti JP; Zhu X; Almodovar AJ; Veldhuis PP; Sause R; Griffith E; Corpus G; Chang JC; Fanaian N; Litherland SA
    Pancreas; 2017 Jan; 46(1):116-123. PubMed ID: 27400259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.
    Allenson K; Castillo J; San Lucas FA; Scelo G; Kim DU; Bernard V; Davis G; Kumar T; Katz M; Overman MJ; Foretova L; Fabianova E; Holcatova I; Janout V; Meric-Bernstam F; Gascoyne P; Wistuba I; Varadhachary G; Brennan P; Hanash S; Li D; Maitra A; Alvarez H
    Ann Oncol; 2017 Apr; 28(4):741-747. PubMed ID: 28104621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations.
    Kulemann B; Rösch S; Seifert S; Timme S; Bronsert P; Seifert G; Martini V; Kuvendjiska J; Glatz T; Hussung S; Fritsch R; Becker H; Pitman MB; Hoeppner J
    Sci Rep; 2017 Jul; 7(1):4510. PubMed ID: 28674438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing.
    Yu J; Gemenetzis G; Kinny-Köster B; Habib JR; Groot VP; Teinor J; Yin L; Pu N; Hasanain A; van Oosten F; Javed AA; Weiss MJ; Burkhart RA; Burns WR; Goggins M; He J; Wolfgang CL
    Cancer Lett; 2020 Nov; 493():245-253. PubMed ID: 32896616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
    Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G
    Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.
    Hussung S; Akhoundova D; Hipp J; Follo M; Klar RFU; Philipp U; Scherer F; von Bubnoff N; Duyster J; Boerries M; Wittel U; Fritsch RM
    BMC Cancer; 2021 Jan; 21(1):49. PubMed ID: 33430810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer.
    Riva F; Dronov OI; Khomenko DI; Huguet F; Louvet C; Mariani P; Stern MH; Lantz O; Proudhon C; Pierga JY; Bidard FC
    Mol Oncol; 2016 Mar; 10(3):481-93. PubMed ID: 26856794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
    Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
    Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zeb1 in Stromal Myofibroblasts Promotes
    Sangrador I; Molero X; Campbell F; Franch-Expósito S; Rovira-Rigau M; Samper E; Domínguez-Fraile M; Fillat C; Castells A; Vaquero EC
    Cancer Res; 2018 May; 78(10):2624-2637. PubMed ID: 29490942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.